|
Characteristics
|
Patients with BD in U.S. (RISE) (N = 1323)
|
Patients with BD in Egypt (ECR) [11] (N = 1526)
|
Patients with BD in Turkey [12] (N = 682)
|
Patients with BD in Iran [7] (N = 163)
|
Patients with BD in Japan [13] (N = 135)
|
|---|
|
Sociodemographic
|
Age, mean (SD)
|
48.7 (16.3)
|
35.7 (9.84)
|
33.0 (9.9)
|
NR
|
NR
|
|
Female, N (%)
|
1049 (79.3)
|
424 (27.8)
|
113 (16.6)
|
63 (38.7)
|
78 (57.8)
|
|
Medications
|
Colchicine, N (%)
|
728 (55.0)
|
611 (82.7)
|
599 (87.8)
|
108 (66.3)
|
90 (66.7)
|
|
Dapsone, N (%)
|
62 (4.7)
|
NR
|
NR
|
NR
|
0 (0.0)
|
|
Glucocorticoids, N (%)
|
895 (67.6)
|
947 (90.2)
|
384 (56.3)
|
110 (67.5)
|
78 (57.8)
|
|
cDMARDs, N (%)
| | | | |
1 (0.70)
|
|
Azathioprine, N (%)
|
418 (31.6)
|
474 (26.7)
|
347 (50.8)
|
48 (29.4)
|
17 (12.6)
|
|
Methotrexate, N (%)
|
288 (21.8)
|
67 (7.2)
|
14 (2.1)
|
51 (31.3)
|
9 (6.7)
|
|
Hydroxychloroquine, N (%)
|
117 (8.8)
|
NR
|
NR
|
NR
|
NR
|
|
Sulfasalazine, N (%)
|
53 (4.0)
|
NR
|
51 (7.5)
|
3 (5.4)
|
31 (23.0)
|
|
Mycophenolate, N (%)
|
31 (2.3)
|
NR
|
NR
|
0 (0.0)
|
0 (0.0)
|
|
Leflunomide
|
26 (1.9)
|
NR
|
NR
|
NR
|
NR
|
|
Cyclosporine, N (%)
|
23 (1.5)
|
282 (26.7)
|
93 (13.6)
|
13 (8.0)
|
14 (10.4)
|
|
Cyclophosphamide, N (%)
|
< 10
|
208 (20.1)
|
39 (5.7)
|
39 (23.9)
|
0 (0.0)
|
|
Minocycline, N (%)
|
< 10
|
NR
|
NR
|
NR
|
NR
|
|
Tacrolimus, N (%)
|
11 (0.83)
|
NR
|
NR
|
NR
|
NR
|
|
Biologics-TNFi, N (%)
|
389 (29.4)
|
83 (8.3)
|
NR
|
1 (0.60)
|
NR
|
|
Infliximab, N (%)
|
192 (14.5)
|
NR
|
4 (0.6)
|
NR
|
NR
|
|
Adalimumab, N (%)
|
187 (14.1)
|
NR
|
NR
|
NR
|
10 (7.4)
|
|
Etanercept, N (%)
|
92 (6.9)
|
NR
|
NR
|
NR
|
1 (0.70)
|
|
Golimumab, N (%)
|
20 (1.5)
|
NR
|
NR
|
NR
|
0 (0.0)
|
|
Certolizumab, N (%)
|
30 (2.3)
|
NR
|
NR
|
NR
|
NR
|
|
Biologics-non-TNFia, N (%)
|
59 (4.5)
|
NR
|
NR
|
NR
|
NR
|
|
tsDMARDs
|
53 (4.0)
|
NR
|
NR
|
NR
|
NR
|
- RISE Rheumatology Informatics System for Effectiveness, ECR Egyptian College of Rheumatology, csDMARDs conventional disease modifying anti-rheumatic drugs, TNFi tumor necrosis factor inhibitors, NR non recorded
- aBiologics-non-TNFi include rituximab, abatacept, tocilizumab, ustekinumab, and secukinumab
